Title: Venus Commercial Co., Inc. v. The Department of Health and the Food and Drug Administration

### Facts:

Venus Commercial Co., Inc. (Venus) found itself in contention with the Department of Health (DOH) and the Food and Drug Administration (FDA) following the issuance of FDA Personnel Order No. 2014-220. This dispute originated from a letter by the EcoWaste Coalition to the FDA regarding the allegedly high lead content in Venus's Artex Fine Water Colors. No FDA approval was on record for these products. Acting on the complaint, the FDA conducted laboratory tests on purchased samples of the subject water colors, which revealed lead content exceeding allowed limits. Consequently, the FDA attempted to enforce FDA Personnel Order No. 2014-220 to enter Venus' premises for inspection and possible seizure of the said water colors, citing public health safety concerns. Venus resisted, arguing constitutional rights violations, specifically against illegal search and seizure and due process. Venus took the matter to court, challenging the constitutionality of certain provisions under the Republic Acts 9711 and 3720, and their Implementing Rules and Regulations, ultimately leading the case to the Supreme Court.

# Issues:

- 1. Whether Sections 12(a) and 30(4) of RA 3720 (as amended by RA 9711) and Section 2(b), paragraph 5 of its IRR violate the constitutional prohibition against unreasonable searches and seizures.
- 2. Whether Section 10(ff) of RA 3720 (as amended) constitutes an invalid delegation of legislative power.
- 3. Whether FDA Personnel Order No. 2014-220 infringes on the guarantees of due process and the right against self-incrimination.

## Court's Decision:

The Supreme Court upheld the constitutionality of the challenged provisions and FDA's actions. The Court ruled:

1. The challenged sections do not infringe on the constitutional prohibition against unreasonable searches and seizures. Administrative or regulatory searches of commercial premises, particularly in closely regulated industries like those overseen by the FDA, can be effected without a warrant, within the bounds of reasonableness, for public health and safety.

- 2. Section 10(ff) does not constitute an undue delegation of legislative power. The law is complete and provides sufficient standards for the FDA to determine its regulatory scope, specifically defining the term "health products" and implicitly including within this domain products that the FDA determines may have an impact on health.
- 3. FDA Personnel Order No. 2014-220 does not violate due process or the right against self-incrimination. The Court pointed out that administrative actions taken for public welfare need not always be preceded by a notice and hearing, provided these actions are temporary and subject to later judicial scrutiny. The Court also noted that the right against self-incrimination was not applicable in this case since the order had not yet been executed and was aimed at safeguarding public health, not criminally prosecuting Venus.

## Doctrine:

The decision reiterated the principle that the government, through its agencies, can conduct warrantless administrative searches in the interest of public health and safety, especially within closely regulated industries. It also affirmed that legislative powers can be delegated conditionally, provided laws set a clear policy and a sufficient standard for executing the delegated authority.

### Class Notes:

- Administrative searches: Regulatory inspections by state agencies may not require a warrant if they are reasonable and in pursuit of significant public interests.
- Delegation of legislative power: For a delegation to be valid, the law must be complete in itself and must establish sufficient standards for the implementing body.
- Due process in administrative actions: The requirement of notice and hearing may be dispensed with in certain regulatory actions addressing urgent public welfare concerns.

# Historical Background:

The legal challenge in this case arose from the evolving framework of the FDA's authority to regulate health products in the Philippines, reflecting the principle that legislative frameworks must adapt to modern health and safety standards. The outcome underscores the balance between constitutional rights and the necessity of regulatory oversight for public welfare.